The hepatitis B virus core protein (HBc), also named core antigen, is well-known for its key role in viral capsid formation and virus replication. Recently, studies showed that HBc has the potential to control cell biology activity by regulating host gene expression. Here, we utilized miRNA microarray to identify 24 upregulated miRNAs and 21 downregulated miRNAs in HBc-expressed HCC cells, which were involved in multiple biological processes, including cell motility. Consistently, the in vitro transwell assay and the in vivo tail-vein injection model showed HBc promotion on HCC metastasis. Further, the miRNA-target gene network analysis displayed that the deleted in liver cancer (DLC-1) gene, an important negative regulator for cell motility, was potentially targeted by several differentially expressed miRNAs in HBc-introduced cells. Introduction of miRNAs mimics or inhibitors and 3'UTR luciferase activity assay proved that miR-382-5p efficiently suppressed DLC-1 expression and its 3'-UTR luciferase reporter activity. Importantly, cotransfection of miR-382-5p mimics/inhibitors and the DLC-1 expression vector almost abrogated HBc promotion on cell motility, indicating that the miR-382-5p/DLC-1 axis is important for mediating HBc-enhanced HCC motility. Clinical HCC samples also showed a negative correlation between miR-382-5p and DLC-1 expression level.
Introduction
More than 350 million people are chronically infected with hepatitis B virus (HBV), which is a major cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC) [1] . To date, the molecular mechanisms of chronic HBV infection and its related liver diseases still remain to be comprehensively elucidated. HBV is a small DNA virus with a 3.2kb genome, which includes four partially overlapping open reading frames and encodes the envelop (pre-S/S), core (precore/core), polymerase (P) and X (HBx) proteins [2] . Integration of HBV DNA into the host genome and persistent expression of viral proteins induce genetic instability, altered expression or activation of cancer-related molecules or pathways, and improper immune responses, which in turn leads to hepatocyte destruction-regeneration and transformation [3] . Recently, accumulated epigenetic alterations, including DNA methylation, histone modification and non-coding RNA (miRNA, lncRNA),were reported to have profound significances in HBV-related carcinogenesis [4] .
MicroRNAs (miRNAs), a class of naturally occurring, non-coding RNA molecules of about 21-25 nucleotides in length, were first described in 1993 by Lee and colleagues [5] .Through its partially complementary sequence to the 3'-UTR of target mRNAs, miRNAs result in gene silencing via translational repression and/or mRNA degradation and then are involved in regulating almost all known physiological and pathological processes [6] . Specifically, emerging evidences disclosed that aberrant expression of miRNAs contributes to HBV-associated hepatocarcinogenic process.
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High accuracy of a panel of 7 miRNAs (miR-122,miR-192, miR-21, miR-223, miR-26a and miR-801) in the diagnosis of HBV-related HCC indicates their close correlation with HCC development [7] . At the cellular level, HBV viral proteins, especially HBx, were shown to regulate the host miRNAs expression level, which then might promote the malignant phenotype of hepatocyte [8] . For example, let-7a, one of the most well-known tumor suppressor miRNA, was downregulated by HBx.
This downregulation of let-7a subsequently activated the JAK/STAT3 pathway and enhanced the proliferation of HCC cells [9] . On the contrary, miR-27a, significantly upregulated in HBV-infected HCC patients, promoted cell proliferation, migration, invasion and cell cycle entry [10] . Thus, it would be of great concern to uncover the HBV-regulated miRNAs and to elucidate their biological functions in HBV-related HCC.
The hepatitis B virus core protein (HBc), also named core antigen, is well-known for its key role in viral capsid formation and virus replication regulation 
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Material and methods
Cell lines
The human HCC cell lines, HepG2 and BEL7402 cells were cultured in RPMI A C C E P T E D M A N U S C R I P T streptomycin (Invitrogen, Beijing, China). Cells were grown with 5% CO 2 at 37°C.
Plasmids, Oligonucleotides and transfections
The plasmid pcDNA-HBc-HA, containing an HA-tagged, HBc gene of HBV genotype C, was generated as described previously [15] . The pcDNA3-DLC-1 expression vector was gifted from Prof. Douglas R. Lowy (National Cancer Institute, Bethesda). For the 3'-UTR luciferase assay, the 3'-UTR region of DLC-1 genes was PCR amplified with human cDNAs, followed by pGL3-promoter vectors.
Transfections were performed using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions.
A 16-mer PS-ODN, complementary to HBc poly-A region of HBV genome, called as-HBc, and a random 16-mer PS-ODNs, unrelated to the HBV sequence, called as-rODN, was designed and synthesized as described previously [16] .
MiRNA mimics, inhibitors or the corresponding negative controls (NC) were synthesized by Genepharma (Shanghai, China) and transfected with PepMuteTM siRNA Transfection Reagent (signaGen, USA) according to the manufacturer's instructions.
miRNA microarray analysis
Total RNA was isolated from pcDNA3 or pcDNA3-HBc transfected BEL7402 cells with TRIZOL reagent (Invitrogen, Beijing, China). Then, RNA was labeled with Cy3, concentrated (Qiagen,Shanghai, China), and hybridized with miRCURYTM
Array microarray (Exiqon, Denmark). The slide, scanned by using the Genepix 4000B, was analyzed with Genepix Pro 6.0. A mean value ratio between the pcDNA3 and
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Real-time PCR analysis
Real-time PCR was performed on a CFX96 Touch Real-Time PCR Detection System (Bio-Rad, USA) using the LightCycler FastStart DNA Master SYBR Green I kit (TIANGEN, China). The relative expression level of the DLC-1 gene is normalized to β-actin. The relative expression of miRNAs was normalized to U6 RNA.
Western blot
Cell extracts were prepared and analyzed by western blot as described previously
[6], using anti-human DLC-1(Santa Cruz Biotechnology, USA) and anti-β-actin (Santa Cruz Biotechnology, USA).
Transwell assay
HepG2 or BEL7402 cell suspension was prepared and a transwell assay was performed as described previously [17].
Immunofluorescence staining and microscopy
Cells seeded on cover slips were fixed with 2% paraformaldehyde, permeabilized with 0.2% Triton X-100 in phosphate-buffered saline (PBS) and then stained with A C C E P T E D M A N U S C R I P T
2.8In vivo metastasis assay
Six-to 8-week-old male BALB/c nude mice were housed in the animal facilities of the Department of Immunology Shandong University under pathogen-free conditions.
All procedures were pre-approved by the Institutional Animal Care and Use
Committee. Two million of HepG2 cells stably transfected with pcDNA3-HBc or pcDNA3empty vector were injected into BALB/c nude mice through tail veins (n = 5 per group). After 6 weeks, mice were sacrificed and the lungs were dissected and stained with Bouins solution. Then, the number of tumor nodules in the lungs was counted and the tumor nodules were re-confirmed by HE staining. Results were presented as mean firefly luciferase intensity relative to renilla luciferase activity. Each experiment was performed in triplicate wells, and the mean value was expressed from three independent experiments.
2.9Luciferase reporter assay
2.10Patients
Tumor tissues were collected from patients with primary HCC, which was determined according to the criteria described by Edmondson and Steiner [18] . HBc, DLC-1 and miRNA expression level was detected using real-time PCR.
Statistical analysis
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A C C E P T E D M A N U S C R I P T Statistical analyses were performed using GraphPad Prism 5 (GraphPad Software Inc., San Diego, CA, USA) and SPSS v.20.0(SPSS Inc., Chicago, IL, USA). The differences between groups were determined by Student's t-test or Mann-Whitney U test. P values < 0.05 was considered to be statistically significant. 
Results
Deregulated miRNAs induced by
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[15].Interestingly, both GO and pathway analyses disclosed that besides cell growth, HBc might be involved in regulating cell motility via altering the miRNA profile and their targeted genes or pathways in hepatocytes.
HBc promoted HCC motility both in vitro and in vivo
Based on above microarray data, we performed an in vitro transwell assay to validate whether HBc plays a role in regulating cell motility. As shown in Figure 2A and 2B, transfection of HBc significantly enhanced the migration and invasion of Figure 2D and 2E,pulmonary metastatic tumors in the HBc group significantly outnumbered those in pcDNA3 controls. The tumor nodules in lung were further verified by HE staining ( Figure 2F ). Taken together, our in vivo data supplemented the promotion of HBc on HCC metastasis.
DLC-1 was one of key target genes in HBc-regulated miRNA network
In order to explore the mechanisms of HBc promotion on HCC motility, we applied
Pearson correlation analysis to the HBc-deregulated miRNA and mRNA genes that ACCEPTED MANUSCRIPT
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were displayed in the microarray analysis (mRNA microarray data were shown in our previous work [15] ). Then, the overlapping miRNA-mRNA pairs that showed negative correlation were included in the miRNA-target gene network as shown in Figure 3A . Interestingly, among these interaction networks, we found that the gene deleted in liver cancer 1 (DLC-1), downregulated in HBc-expressed BEL7402 cells by more than 3-fold, was predicted to be targeted by several HBc-upregulated miRNAs, indicating that DLC-1 might be an important potential target gene in the HBc-mediated miRNA-mRNA network.
Also, considering the established role of DLC-1 in regulating cell motility, we hypothesized that DLC-1might be an important mediator for HBc promotion on HCC metastasis. Thus, we first verified the downregulation of DLC-1 by HBc expression in both BEL7402 cells and HepG2 cells. As shown in Figure 3B and C, HBc significantly reduced the expression of DLC-1 mRNA and protein in both cell lines.
Consistently, knockdown of HBc, using an antisense oligonucleotide specific to HBc gene, named PS-asODNs/HBc, significantly upregulated DLC-1 expression in HepG2.2.15 cells ( Figure 3D ).Furthermore, DLC-1 expression in the liver of HBV transgenic mice significantly decreased as compared with that in wild mice( Figure   3E ). Taken together, these results showed the suppression of HBc on DLC-1 expression, supporting the hypothesis that DLC-1 might be one of the key target genes regulated by the HBc-miRNAs network.
Upregulated miR-382-5p was crucial for HBc-mediated DLC-1 suppression
To further clarify the regulation network of HBc on DLC-1 expression, we selected ACCEPTED MANUSCRIPT
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three miRNAs, miR-19b-3p, miR-382-5p, and miR-766-3p,which were predicted to target the DLC-1 gene and upregulated in our miRNA microarray data, and validated the influence of HBc on their expression. Real-time PCR showed that, consistent with the microarray data, the expression of miR-19b-3p,miR-382-5p, and miR-766-3p
were significantly upregulated after HBc transfection in both HepG2 ( Figure 4A ) and BEL7402 cells ( Figure 4B ). Next, specific mimics were used to confirm the regulation of miR-19b-3p, miR-382-5p, and miR-766-3p on DLC-1 expression. As shown in Figure 4C , compared to control cells, the introduction of miR-19b-3p and miR-382-5pmimics, but not miR-766-3p mimics, significantly reduced DLC-1 expression. Then, the inhibitors, specific for miR-19b-3p and miR-382-5p, were administrated to further verify their regulatory roles on DLC-1. We found that only the miR-382-5p inhibitor enhanced DLC-1 expression ( Figure 4D ). In accordance, the dual-luciferase assay showed that HBc significantly inhibited the luciferase activity of DLC-1 3'-UTR( Figure 4E ).MiR-382-5p mimics also showed the suppressive effect on the DLC-1 3'-UTR activity and vice versa ( Figure 4E ). More importantly, the suppression of HBc on DLC-1 3'-UTR luciferase activity was almost abrogated by co-transfection of the miR-382-5p mimics or inhibitor ( Figure 4E ). Consistently, the expression of DLC-1mRNA and protein in HBc-transfected cells was leveled to a similar degree with pcDNA3 control cells by miR-382-5p mimicsor inhibitor ( Figure   4F and 4G). Collectively, these results support the argument that HBc-mediated miR-382-5p upregulation is, at least partially, responsible for its suppression on DLC-1 expression.
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miR-382-5p/DLC-1 axis was involved in HBc-enhanced HCC migration
Although little is known about the role of miR-382-5p in HCC development, its regulation on DLC-1 expression indicated that miR-382-5p might be associated with HCC cell motility. Thus, we first detected the effect of the miR-382-5p/DLC-1 axis on the motility of HCC cells using a transwell assay. As shown in Figure 5A and 5B, miR-382-5p mimics significantly boosted the migration and invasion of BEL7402 and HepG2 cells, while DLC-1 overexpression restored miR-382-5p-enhanced cell migration and invasion to the similar level of negative control cells. Moreover, miR-382-5p mimics promote the accumulation of F-actin, while DLC-1 abolished this effect ( Figure 5C ).
To further explore the functional connection between HBc and the miR-382-5p/DLC-1 axis, we first investigated whether miR-382-5p upregulation participates in the motility-promoting effects of HBc. A transwell assay showed that both miR-382-5p inhibitors almost neutralized the enhanced effects of HBc on the migration and invasion ability of BEL7402 cells ( Figure 5D and E). Similar results were also found in HepG2 cells ( Figure 5F and G). Next, we verified the involvement of DLC-1 downregulation in HBc regulation on cell motility. As shown in Figure 5H and 5I, DLC-1 overexpression almost abrogated the promotion of HBc on cell migration and invasion in both BEL7402 and HepG2 cells. Again, phalloidin staining further verified DLC-1 neutralization on HBc-enhanced F-actin accumulation ( Figure   5J ). Collectively, these results suggest that miR-382-5p/DLC-1 axis regulated by HBc expression is crucial for its influence on HCC metastasis.
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Discussion
Cancer metastasis is the major cause for the morbidity and mortality of the patients, domain and a START (StAR-related lipid-transfer) domain [27] . RhoGAP activity of DLC-1 appears to be responsible for regulating cell morphology and adhesion [28] .
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The loss of DLC-1 may lead to aberrant Rho GTPase function and contribute to the abnormal migration and metastatic properties of cancer cells [27] . Here we found that
HBc significantly decreased DLC-1 expression in HCC cell lines ( Figure 3B-E In clinical HCC samples, we further found that miR-382-5p levels had apositive correlation with HBc and a negative correlation with DLC-1 expression (Figure 6 ).
Hsa-miR-382, located on chromosome 14q32, has proved to be involved in different ACCEPTED MANUSCRIPT
physiological or pathological processes, such as virus latency [31] , alcohol addiction [32] , cholesterol homeostasis [33] , and tumorigenesis. Upregulation of miR-382-5p
was observed in patients with myeloid neoplasms [34] , in macrophage-derived foam cells [35] ,and in hypoxia condition [36] . Moreover, HIF-1α-mediated transcription activation and lncRNA RP5-833A20.1-mediated post-transcriptional mechanisms were shown to be involved in regulating miR-382-5p expression [35, 36] . However, In conclusion, we first identified the regulatory role of HBc on host miRNA profile.
Moreover, HBc-mediated miR-382-5p upregulation and subsequent DLC-1 suppression were found to be involved in its promotion on HCC motility (Figure 7 ).
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